Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Relative Bioavailability of a Single-dose Administration of BIBW 2992 and Multiple-dose Administration of Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BIBW 2992
Drug: Ritonavir

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT02171754

Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773
Drug: Glimepiride

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02172261

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT02172105

Bioavailability and Pharmacokinetics of BI 10773 Tablet in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 10773

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02172209

Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Spiriva

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 10821

Registration Number: NCT02172547

Dose Escalation Study of Continuous Once-daily Oral Treatment With BIBW 2992 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: BIBW 2992

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02171728

Relative Bioavailability of Single Oral Doses of Dabigatran Etexilate With or Without Oral Administration of Verapamil in Two Different Dosages in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: dabigatran
Drug: Verapamil
Drug: Verapamil ER

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 40

Registration Number: NCT02171533

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1744 CL
Drug: Placebo

First Posted Date: 2014-06-24

Last Posted Date: 2014-06-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 47

Registration Number: NCT02171806

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Dabigatran etexilate powder
Drug: Dabigatran etexilate capsule
Drug: Dabigatran etexilate pellets

First Posted Date: 2014-06-24

Last Posted Date: 2017-05-23

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT02171611

Spiriva® in Patients With Chronic Obstructive Pulmonary Disease (COPD) in Daily Practice

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Tiotropium bromide

First Posted Date: 2014-06-24

Last Posted Date: 2018-08-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 4700

Registration Number: NCT02172495

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy